Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, placebo-controlled, double-blind, parallel-group study, to assess efficacy, safety and immunogenicity of JNJ-64042056, a phosphorylated tau targeted active immunotherapy, in participants with preclinical Alzheimer's disease

Next Previous
Search
Trial Profile

A multicenter, randomized, placebo-controlled, double-blind, parallel-group study, to assess efficacy, safety and immunogenicity of JNJ-64042056, a phosphorylated tau targeted active immunotherapy, in participants with preclinical Alzheimer's disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACI 35.030 (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ReTain
  • Sponsors AC Immune; Janssen-Cilag

    • Most Recent Events

    • 25 Mar 2025 According to an AC Immune media release, data from this study will be presented at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2025) taking place in Vienna, Austria, on April 1-5, 2025
    • 08 Jan 2025 According to an AC Immune media release, company announced that the USFDA has granted Fast Track designation in July 2024.
    • 17 Sep 2024 According to an AC Immune media release, company today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top